Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

Pacific Biosciences' Q4'24 results missed estimates. Growth in genetic data usage noted, but research funding uncertainties pose risks. See more on PACB stock here.

New York State Common Retirement Fund raised its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings ... fast-growing enterprise software stock that is already riding the automation wave and looking ...

Bernstein analyst Eve Burstein maintained a Buy rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $2.00.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio ...

PACB ended the quarter with 270 cumulative Revio ... These look promising for the stock. Yet, the continued loss per share reported by PacBio was disappointing. The year-over-year fall in the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...